{
  "source": "PA-Med-Nec-Skyrizi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2205-8\nProgram Prior Authorization/Medical Necessity\nMedication *Skyrizi® (risankizumab-rzaa) injection\n*This program applies to the subcutaneous formulations of Skyrizi\nP&T Approval Date 5/2020, 5/2021, 6/2021, 3/2022, 8/2022, 7/2023, 5/2024, 7/2024\nEffective Date 10/1/2024\n1. Background:\nSkyrizi is an interleukin-23 antagonist indicated for the treatment of moderate to severe plaque\npsoriasis in adults who are candidates for systemic therapy or phototherapy, active psoriatic\narthritis in adults, moderately to severely active Crohn's disease in adults, and moderately to\nseverely active ulcerative colitis in adults.\n2. Coverage Criteriaa:\nA. Plaque Psoriasis\n1. Initial Authorization\na. Skyrizi will be approved based on all of the following criteria:\n(1) Diagnosis of moderate to severe plaque psoriasis\n-AND-\n(2) One of the following:\n(a) All of the following:\ni. Greater than or equal to 3% body surface area involvement,\npalmoplantar, facial, genital involvement, or severe scalp psoriasis\n-AND-\nii. History of failure to one of the following topical therapies, unless\ncontraindicated or clinically significant adverse effects are experienced\n(document drug, date, and duration of trial):\na. Corticosteroids (e.g., betamethasone, clobetasol, desonide)\nb. Vitamin D analogs (e.g., calcitriol, calcipotriene)\nc. Tazarotene\nd. Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)\ne. Anthralin\nf. Coal tar\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n1\niii. History of failure to a 3 month trial of methotrexate at maximally\nindicated dose, unless contraindicated or clinically significant adverse\neffects are experienced (document date and duration of trial)b\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of plaque psoriasis as documented by claims\nhistory or submission of medical records (Document drug, date, and\nduration of therapy) [e.g., Cimzi",
    "argeted immunomodulator FDA-\napproved for the treatment of plaque psoriasis as documented by claims\nhistory or submission of medical records (Document drug, date, and\nduration of therapy) [e.g., Cimzia (certolizumab), adalimumab, Stelara\n(ustekinumab), Tremfya (guselkumab)].\n-OR-\n(c) Both of the following:\ni. Patient is currently on Skyrizi therapy as documented by claims history or\nsubmission of medical records (Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in\nthe prescriber’s office, or any form of assistance from the Abbvie\nsponsored Skyrizi Complete program (e.g., sample card which can be\nredeemed at a pharmacy for a free supply of medication) as a means\nto establish as a current user of Skyrizi*\n-AND-\n(3) Patient is not receiving Skyrizi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Stelara\n(ustekinumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz\n(ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla\n(apremilast)]\n-AND-\n(4) Prescribed by or in consultation with a dermatologist\n* Patients requesting initial authorization who were established on therapy via the\nreceipt of a manufacturer supplied sample at no cost in the prescriber’s office or any\nform of assistance from the Abbvie sponsored Skyrizi Complete program shall be\nrequired to meet initial authorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n2\n2. Reauthorization\na. Skyrizi will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Skyrizi therapy\n-AND-\n(2) Patient is not receiving Skyrizi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(go",
    "tive clinical response to Skyrizi therapy\n-AND-\n(2) Patient is not receiving Skyrizi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab),\nTremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq\n(brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\nB. Psoriatic Arthritis (PsA)\n1. Initial Authorization\na. Skyrizi will be approved based on all of the following criteria:\n(1) Diagnosis of active psoriatic arthritis\n-AND-\n(3) One of the following:\n(a) History of failure to a 3 month trial of methotrexate at the maximally\nindicated dose, unless contraindicated or clinically significant adverse effects\nare experienced (document date and duration of trial)b\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of psoriatic arthritis as documented by claims\nhistory or submission of medical records (Document drug, date, and\nduration of therapy) [e.g., adalimumab, Cimzia (certolizumab), Rinvoq\n(upadacitinib), Simponi (golimumab), Stelara (ustekinumab), Tremfya\n(guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Otezla (apremilast),\nRinvoq (upadacitinib)]\n-OR-\n(c) Both of the following:\ni. Patient is currently on Skyrizi therapy as documented by claims history\nor submission of medical records (Document date and duration of\ntherapy):\n© 2024 UnitedHealthcare Services, Inc.\n3\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the Abbvie sponsored\nSkyrizi Complete program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of Skyrizi*\n-AND-\n(3) Patient is not receiving Skyrizi in combination with another targeted\ni",
    "h can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of Skyrizi*\n-AND-\n(3) Patient is not receiving Skyrizi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab), Tremfya\n(guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]\n-AND-\n(4) Prescribed by or in consultation with one of the following:\n(a) Rheumatologist\n(b) Dermatologist\n* Patients requesting initial authorization who were established on therapy via the\nreceipt of a manufacturer supplied sample at no cost in the prescriber’s office or any\nform of assistance from the Abbvie sponsored Skyrizi Complete program shall be\nrequired to meet initial authorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Skyrizi will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Skyrizi therapy\n-AND-\n(2) Patient is not receiving Skyrizi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Stelara\n(ustekinumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz\n(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n4\nC. Crohn’s Disease (CD)\n1. Initial Authorization for Maintenance Dosing\na. Skyrizi will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active Crohn’s disease\n-AND-\n(2) One of the following:\n(a) Patient has been established on therapy with Skyrizi under an active\nUnitedHealthcare prior authorization for the treatment of moderately to\nseverely active ",
    "isease\n-AND-\n(2) One of the following:\n(a) Patient has been established on therapy with Skyrizi under an active\nUnitedHealthcare prior authorization for the treatment of moderately to\nseverely active Crohn’s disease\n-OR-\n(b) Both of the following:\ni. Patient is currently on Skyrizi therapy for moderately to severely active\nCrohn’s disease as documented by claims history or submission of\nmedical records (Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the Abbvie sponsored\nSkyrizi Complete program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of Skyrizi*\n-AND-\n(3) Patient is not receiving Skyrizi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Stelara\n(ustekinumab)]\n-AND-\n(4) Prescribed by or in consultation with a gastroenterologist\n* Patients requesting initial authorization who were established on therapy via the\nreceipt of a manufacturer supplied sample at no cost in the prescriber’s office or any\nform of assistance from the Abbvie sponsored Skyrizi Complete program shall be\nrequired to meet initial authorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n5\n2. Reauthorization\na. Skyrizi will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Skyrizi therapy\n-AND-\n(2) Patient is not receiving Skyrizi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Stelara\n(ustekinumab)]",
    "or [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Stelara\n(ustekinumab)]\nAuthorization will be issued for 12 months.\nD. Ulcerative Colitis (UC)\n1. Initial Authorization for Maintenance Dosing\na. Skyrizi will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active ulcerative colitis\n-AND-\n(2) One of the following:\n(a) Patient has been established on therapy with Skyrizi under an active\nUnitedHealthcare medical benefit prior authorization for the treatment\nof moderately to severely active ulcerative colitis\n-OR-\n(b) Both of the following:\ni. Patient is currently on Skyrizi therapy for moderately to severely active\nulcerative colitis as documented by claims history or submission of\nmedical records (Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the Abbvie sponsored\nSkyrizi Complete program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of Skyrizi*\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n6\n(3) Patient is not receiving Skyrizi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib), Stelara (ustekinumab), adalimumab]\n-AND-\n(4) Prescribed by or in consultation with a gastroenterologist\n* Patients requesting initial authorization who were established on therapy via the\nreceipt of a manufacturer supplied sample at no cost in the prescriber’s office or any\nform of assistance from the Abbvie sponsored Skyrizi Complete program shall be\nrequired to meet initial authorization criteria as if patient were new to therapy.\nAuthorization will be i",
    " office or any\nform of assistance from the Abbvie sponsored Skyrizi Complete program shall be\nrequired to meet initial authorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Skyrizi will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Skyrizi therapy\n-AND-\n(2) Patient is not receiving Skyrizi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib), Stelara (ustekinumab), adalimumab]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\nb For Connecticut, Kentucky, and Mississippi business only a 30-day trial will be required.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Skyrizi [package insert]. North Chicago, IL: AbbVie Inc.; June 2024.\n2. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of\npsoriasis with biologics. J Am Acad Dermatol 2008; 58(5):826-50.\n© 2024 UnitedHealthcare Services, Inc.\n7\n3. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis\nand psoriatic arthritis. Psoriatic arthritis: Overview and guidelines of care for treatment with an\nemphasis on the biologics. J Am Acad Dermatol 2008;5",
    "delines of care for the management of psoriasis\nand psoriatic arthritis. Psoriatic arthritis: Overview and guidelines of care for treatment with an\nemphasis on the biologics. J Am Acad Dermatol 2008;58(5):851-64.\n4. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis\nwith topical therapies. J Am Acad Dermatol 2009;60(4):643-59.\n5. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis. Guidelines of care for the treatment of psoriasis with phototherapy and\nphotochemotherapy. J Am Acad Dermatol 2010;62(1):114-35.\n6. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis. Guidelines of care for the management and treatment of psoriasis with\ntraditional systemic agents. J Am Acad Dermatol 2009;61(3):451-85.\n7. Nast A, et al; European S3-Guidelines on the systemic treatment of psoriasis vulgaris – update\n2015 – short version – EFF in cooperation with EADV and IPC, J Eur Acad Derm Venereol\n2015;29:2277-94.\n8. Menter A, Korman NJ, Elmets CA,Feldman SR, Gelfand JM, Gordon KB, Guidelines of care for\nthe management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment\nof psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J\nAm Acad Dermatol. 2011 Jul;65(1):137-74.\n9. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management\nand treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-72.\n10. Lichtenstein GR, Loftus EV, Isaacs KL, et al ACG clinical guideline: management of Crohn’s\ndisease in adults. Am J Gastroenterol. 2018; 113:481-517.\nProgram Prior Authorization/Medical Necessity – Skyrizi® (risankizumab-rzaa)\nChange Control\n5/2020 New program\n5/2021 Annual review. Removed preceding month requirement ",
    "troenterol. 2018; 113:481-517.\nProgram Prior Authorization/Medical Necessity – Skyrizi® (risankizumab-rzaa)\nChange Control\n5/2020 New program\n5/2021 Annual review. Removed preceding month requirement from failure\ncriteria. Removed prescriber requirement from reauthorization criteria.\nRemoved drug documentation where only one drug is required.\nReference updated.\n6/2021 Added coverage criteria for patients previously treated with a biologic\nDMARD. Added clarification that submission of medical records is\nrequired documenting previous or current therapy with a biologic\nDMARD in order to bypass step through non-biologic therapies if claim\nhistory not available.\n3/2022 Clinical coverage criteria updated to add active psoriatic arthritis.\nUpdated reference.\n8/2022 Clinical coverage criteria and background updated to add Crohn’s\ndisease. Added state mandate footnote to include Mississippi. Added\nRinvoq as Janus kinase inhibitor example. Updated reference.\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n5/2024 Annual review with no changes to coverage criteria. Updated state\nmandate footnote and references.\n7/2024 Updated clinical coverage criteria and background to add ulcerative\ncolitis. Updated active prior authorization verbiage under Crohn’s\ndisease with no change to clinical intent. Updated reference.\n© 2024 UnitedHealthcare Services, Inc.\n8"
  ]
}